Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

By Joe Y. Chang, S. Senan, M. Paul, R. Mehran, A. Louie, P. Balter, H. Groen, S. McRae, J. Widder, Lei Feng and 15 more. The Lancet Oncology, 2015

1,364 citations recorded by the source corpus.

Subfields: Hepatology, Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/21ecafbb497fdddf9c91b7cc1d11a28807d360e8

Citations in the corpus

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “A pooled analysis of two of the closed trials, the STARS and ROSEL studies, revealed comparable recurrence-free survival at 3 years [94].”